Clément Anfray graduated in Biomedical Sciences in 2014 and received a PhD in Molecular and Cellular Biology in 2017 at the University of Caen-Normandy (France). He joined the group in 2018. His work is focused on the delivery of nano-immunotherapies to tumor-associated macrophages in experimental models of lung cancer  for the re-programming of macrophages.